All In Biotech

Drug Trial Radar · NCT04453085

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I

Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Oct 28, 2021

Primary completion

May 2, 2025

Study completion May 2, 2025

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 (NCT04227600) for the treatment of MPS I

Conditions

  • Mucopolysaccharidosis I

Interventions

  • JR-171Drug

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse EventsTime frame: 156 weeks
  2. Incidence of abnormal laboratory test resultsTime frame: 156 weeks
  3. Incidence of abnormal laboratory test resultsTime frame: 156 weeks
  4. Incidence of abnormal laboratory test resultsTime frame: 156 weeks
  5. Incidence of abnormal laboratory test resultsTime frame: 156 weeks
  6. Incidence of abnormal vital signsTime frame: 156 weeks
  7. Incidence of abnormal vital signsTime frame: 156 weeks
  8. Incidence of abnormal vital signsTime frame: 156 weeks
  9. Incidence of abnormal vital signsTime frame: 156 weeks
  10. Incidence of abnormal EKG readingsTime frame: 156 weeks
  11. Number of participants with Adverse EventsTime frame: 156 weeks
  12. Number of participants with Adverse EventsTime frame: 156 weeks
  13. Number of participants with Adverse EventsTime frame: 156 weeks

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil

  • Instituto de Genética e Erros Inatos do Metabolismo - IGEIM

    São Paulo, Brazil

  • Fukuoka Children's Hospital

    Fukuoka, Japan

  • National Hospital Organization Kokura Medical Center

    Kitakyushu, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.